Double-blind investigational anti-arrhythmic + GAP-486

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Arrhythmias

Conditions

Arrhythmias

Trial Timeline

Jun 1, 2005 → Nov 1, 2006

NCT ID

NCT00124891

About Double-blind investigational anti-arrhythmic + GAP-486

Double-blind investigational anti-arrhythmic + GAP-486 is a phase 2 stage product being developed by Pfizer for Arrhythmias. The current trial status is terminated. This product is registered under clinical trial identifier NCT00124891. Target conditions include Arrhythmias.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00124891	Phase 2	Terminated	Jun 1, 2005	Nov 1, 2006	Arrhythmias

Competing Products

2 competing products in Arrhythmias

See all competitors

Product	Company	Stage	Hype Score
Current Domperidone + Current proton pump inhibitor (PPI)	Johnson & Johnson	Pre-clinical	26
Risk of selected safety events	AstraZeneca	Pre-clinical	26